Carbidopa
Generic name: Carbidopa
Brand names: Lodosyn
Dosage form: oral tablet (25 mg)
Drug class:
Dopaminergic antiparkinsonism agents
Usage of Carbidopa
Carbidopa is used with another medicine called Levodopa to treat symptoms of Parkinson's disease, such as stiffness or tremors.
Carbidopa and levodopa are also used to treat Parkinson-like symptoms caused by taking certain medicines or by exposure to poisonous gases or minerals such as carbon monoxide or manganese.
Carbidopa is only used in combination with levodopa and has no effect when used alone.
Carbidopa may also be used for purposes not listed in this medication guide.
Carbidopa side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
The following side effects may occur when carbidopa is taken with levodopa.
Carbidopa may cause serious side effects. Call your doctor at once if you have:
Some people taking carbidopa with levodopa have fallen asleep during normal daytime activities such as working, talking, eating, or driving. Tell your doctor if you have any problems with daytime sleepiness or drowsiness.
You may have increased sexual urges, unusual urges to gamble, or other intense urges while taking carbidopa. Talk with your doctor if this occurs.
You may notice that your sweat, urine, or saliva appears dark in color, such as red, brown, or black. This is not a harmful side effect, but it may cause staining of your clothes or bed sheets.
Common side effects of carbidopa may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Carbidopa
You should not use carbidopa if you are allergic to it, or if you have:
Do not use carbidopa if you have used an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, tranylcypromine, and others.
Tell your doctor if you have ever had:
People with Parkinson's disease may have a higher risk of skin cancer (melanoma). Ask your doctor about skin symptoms to watch for.
It is not known if carbidopa will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
You should not breastfeed while using carbidopa.
Not approved for use by anyone younger than 18 years old.
Relate drugs
- Apokyn
- Apomorphine
- Apomorphine (Subcutaneous)
- Apomorphine (Sublingual)
- Azilect
- Comtan
- Carbidopa
- Carbidopa and levodopa
- Carbidopa and levodopa (Oral)
- Carbidopa and levodopa enteral
- Carbidopa, entacapone, and levodopa
- Dhivy
- Duopa
- Entacapone
- Gocovri
- Inbrija
- Kynmobi
- Levodopa
- Levodopa (Oral)
- Lodosyn
- Mirapex
- Mirapex ER
- Neupro
- Ongentys
- Opicapone
- Osmolex ER
- Parcopa
- Pramipexole
- Rasagiline
- Requip
- Requip XL
- Ropinirole
- Rotigotine
- Rotigotine transdermal
- Rytary
- Safinamide
- Sinemet
- Sinemet 10-100
- Sinemet 25-100
- Sinemet 25-250
- Sinemet CR
- Stalevo 100
- Stalevo 125
- Stalevo 150
- Stalevo 200
- Stalevo 50
- Stalevo 75
- Tasmar
- Tolcapone
- Xadago
How to use Carbidopa
Usual Adult Dose for Parkinsonian Tremor:
Patients on carbidopa-levodopa therapy requiring additional carbidopa:Initial dose: 25 mg orally with the first dose of carbidopa-levodopa each dayMaintenance dose: Additional doses of 12.5 mg or 25 mg may be given with each dose of carbidopa-levodopaMaximum dose: 200 mg orally per dayPatients requiring individual titration of carbidopa and levodopa:Initial dose: 25 mg orally 3 to 4 times a day, given at the same time as levodopaMaximum dose: 200 mg orally per dayComments:-Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day; for patients taking carbidopa-levodopa, the amount of carbidopa in carbidopa-levodopa should be considered when calculating the maximum daily carbidopa dose. -In patients already on levodopa, allow 12 hours between the last dose of levodopa and the initiation of therapy with carbidopa and levodopa.Uses: With carbidopa-levodopa or with levodopa in the treatment of symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism
Warnings
Do not use this medicine if you have used an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, or tranylcypromine.
What other drugs will affect Carbidopa
Using carbidopa with other drugs that make you drowsy can worsen this effect. Ask your doctor before using opioid medication, a sleeping pill, a muscle relaxer, or medicine for anxiety or seizures.
Other drugs may affect carbidopa, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Popular FAQ
The short-acting (immediate-release) formulation of carbidopa/levodopa takes effect within about 20 to 50 minutes. The long-acting (extended-release) formulation starts to work closer to the 50-minute timeframe. Continue reading
The immediate-release (short-acting) form of carbidopa/levodopa is usually taken 3 or 4 times each day, while the extended-release (long-acting) form is typically taken 2 to 4 times each day. Continue reading
Carbidopa/levodopa is unlikely to cause high blood pressure (hypertension). It was reported in less than 1% of patients in clinical trials and is not considered a common adverse reaction related to the drug. Continue reading
The short-acting (immediate-release) formulation of carbidopa/levodopa takes effect within about 20 to 50 minutes. The long-acting (extended-release) formulation starts to work closer to the 50-minute timeframe. Continue reading
The immediate-release (short-acting) form of carbidopa/levodopa is usually taken 3 or 4 times each day, while the extended-release (long-acting) form is typically taken 2 to 4 times each day. Continue reading
Carbidopa/levodopa is unlikely to cause high blood pressure (hypertension). It was reported in less than 1% of patients in clinical trials and is not considered a common adverse reaction related to the drug. Continue reading
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions